Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has shared an announcement.
Solvonis Therapeutics plc announced positive results from its SVN-SDN-14 PTSD programme, identifying three high-performing candidates for in vivo studies. These candidates, which modulate serotonin, dopamine, and noradrenaline, aim to improve therapeutic outcomes for PTSD patients by enhancing pro-social behavior. This development strengthens Solvonis’ position in the biopharmaceutical industry, offering increased flexibility and potential for selecting a best-in-class treatment option for PTSD, thereby enhancing its commercial prospects and impact on stakeholders.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London, focusing on developing novel medicines for addiction and mental health disorders. The company is listed on the London Stock Exchange and targets high-burden neuropsychiatric conditions with significant unmet needs, such as Alcohol Use Disorder and Post-Traumatic Stress Disorder. Solvonis is advancing a pipeline of repurposed and novel compounds, including a preclinical PTSD programme and an AI-supported discovery platform for depression and stimulant use disorders.
Average Trading Volume: 93,560,905
Technical Sentiment Signal: Hold
Current Market Cap: £20.66M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.